FGF17抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: HepG2 cells, Primary antibody: P08325(FGF17 Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

Fibroblast Growth Factor 17 (FGF17) is a member of the FGF family, which comprises 23 secreted signaling proteins regulating cell proliferation, differentiation, survival, and metabolism. FGF17 belongs to the FGF8 subfamily (FGF8. FGF17. FGF18) and functions primarily through binding to FGF receptors (FGFRs) in complex with heparan sulfate proteoglycans. It plays critical roles during embryonic development, particularly in midbrain and limb patterning, as well as in adult tissue homeostasis. Dysregulation of FGF17 has been implicated in developmental disorders, metabolic diseases, and cancers, including colorectal and prostate malignancies.

FGF17 antibodies are immunological tools designed to detect, quantify, or modulate FGF17 activity. Polyclonal and monoclonal variants are widely used in research to study FGF17's spatial-temporal expression patterns via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Neutralizing antibodies specifically block FGF17-FGFR interactions, enabling functional studies to dissect its signaling pathways or assess therapeutic potential. Recent interest in FGF17-targeting antibodies stems from their potential application in treating FGF17-driven pathologies. For example, preclinical studies explore their utility in suppressing tumor growth or mitigating aberrant FGF signaling in skeletal disorders. However, challenges remain in ensuring antibody specificity, minimizing off-target effects on related FGF family members, and optimizing delivery strategies for clinical translation.